Stefan Anker

1 month ago | jamanetwork.com | Stefan Anker |Campus Virchow Klinikum |Tim Friede |Javed Butler

Visual Abstract. Efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency Figure 1.  Recruitment, Randomization, and Follow-Up in the FAIR-HF2 Trial FAIR-HF2 indicates Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality. aThe precise reasons are unknown.

1 month ago | nature.com | Stefan Anker |Javed Butler |Frank Rockhold |Christian Röver |Marius Placzek

AbstractUncertainty remains about the effect of intravenous (IV) iron on outcomes for heart failure (HF) with iron deficiency. Here, we summarize the efficacy and safety of IV iron from six trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEART-FID, and FAIR-HF2) including 7,175 patients. In comparison to prior analyses, this meta-analysis adds new data from FAIR-HF2, uses a harmonized and robust Bayesian approach, and includes individual participant data from 5 trials.

Jan 28, 2025 | onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott

Introduction Iron deficiency (ID) is known to impair mitochondrial energy production and cause adverse cardiac remodelling leading to left ventricular dysfunction.1-4 ID is prevalent in up to 50% of patients with heart failure (HF) and is an independently associated with worse functional status, symptoms, and cardiovascular outcomes irrespective of anaemia.5, 6 The FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure) trial was the first major trial of...

Jan 17, 2025 | onlinelibrary.wiley.com | Robert J. Mentz |Stefan Anker |Bertram Pitt |Peter Rossing

Supporting Information Filename Description ejhf3569-sup-0001-Supinfo.docxWord 2007 document , 620.3 KB Appendix S1. Supporting Information. References 1, , . Detecting and treating lung congestion with kidney failure. Clin J Am Soc Nephrol 2022; 17: 757–765. https://doi.org/10.2215/cjn.14591121 2, , , . Volume overload and adverse outcomes in chronic kidney disease: Clinical observational and animal studies. J Am Heart Assoc 2015; 4:e001918.

Dec 1, 2024 | jacc.org | Wolfram Doehner |Stefan Anker |Javed Butler |Faiez Zannad

References1. "Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial)". Am J Cardiol . 2014;114:1713-1721. 2. "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging". Circulation . 2003;107:1991-1997. 3.